APA

Tutaeva V., Misurin A. V., Michiels J. J., Rozenberg J. M., Sokolova M. A., Ivanova V. L., Kolosheinova T. I., Manakova T. E., Levina A. A., Semenova E. A. & Khoroshko N. D. (20080808). Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. : Hematology (Amsterdam, Netherlands).

Chicago

Tutaeva V, Misurin A V, Michiels J J, Rozenberg J M, Sokolova M A, Ivanova V L, Kolosheinova T I, Manakova T E, Levina A A, Semenova E A and Khoroshko N D. 20080808. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. : Hematology (Amsterdam, Netherlands).

Harvard

Tutaeva V., Misurin A. V., Michiels J. J., Rozenberg J. M., Sokolova M. A., Ivanova V. L., Kolosheinova T. I., Manakova T. E., Levina A. A., Semenova E. A. and Khoroshko N. D. (20080808). Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. : Hematology (Amsterdam, Netherlands).

MLA

Tutaeva V, Misurin A V, Michiels J J, Rozenberg J M, Sokolova M A, Ivanova V L, Kolosheinova T I, Manakova T E, Levina A A, Semenova E A and Khoroshko N D. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. : Hematology (Amsterdam, Netherlands). 20080808.